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Background: In many patients with mild asthma, the low frequency of symptoms and the episodic nature of
exacerbations make adherence to regular maintenance treatment difficult. This often leads to over-reliance on
short-acting β2-agonist (SABA) reliever medication and under-treatment of the underlying inflammation, with poor
control of asthma symptoms and increased risk of exacerbations. The use of budesonide/formoterol ‘as needed’ in
response to symptoms may represent an alternative treatment option for patients with mild asthma.
Methods/design: The SYmbicort Given as needed in Mild Asthma (SYGMA) programme consists of two 52-week,
double-blind, randomised, multicentre, parallel-group, phase 3 trials of patients aged 12 years and older with a
clinical diagnosis of asthma for at least 6 months, who would qualify for treatment with regular inhaled
corticosteroids (ICS). SYGMA1 aims to recruit 3750 patients who will be randomised to placebo twice daily (bid)
plus as-needed budesonide/formoterol 160/4.5 μg, placebo bid plus as-needed terbutaline 0.4 mg, or budesonide
200 μg bid plus as-needed terbutaline 0.4 mg. The primary objective is to demonstrate the superiority of as-needed
budesonide/formoterol over as-needed terbutaline for asthma control, as measured by well-controlled asthma
weeks; a secondary objective is to establish the noninferiority of as-needed budesonide/formoterol versus
maintenance budesonide plus as-needed terbutaline using the same outcome measure. SYGMA2 aims to recruit
4114 patients who will be randomised to placebo bid plus as-needed budesonide/formoterol 160/4.5 μg, or
budesonide 200 μg bid plus as-needed terbutaline 0.4 mg. The primary objective is to demonstrate the
noninferiority of as-needed budesonide/formoterol over budesonide bid plus as-needed terbutaline as measured by
the annualised severe exacerbation rate. In both studies, use of all blinded study inhalers will be recorded
electronically using Turbuhaler® Usage Monitors.
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Discussion: Given the known risks of mild asthma, and known poor adherence with regular inhaled corticosteroids,
the results of the SYGMA programme will help to determine the efficacy and safety of as-needed budesonide/
formoterol therapy in mild asthma. Patient recruitment is complete, and completion of the phase 3 studies is
planned in 2017.
Trial registration: ClinicalTrials.gov identifiers: NCT02149199 SYGMA1 and NCT02224157 SYGMA2. Registered on 16
May 2014 and 19 August 2014, respectively.
Keywords: As-needed, Asthma control, Budesonide/formoterol, Exacerbations, Mild asthma, Prn, Rescue inhaler, SYGMABackground
Approximately 50–75% of patients with asthma are con-
sidered to have mild disease, but the risks, especially of
exacerbations, are often poorly recognised [1]. The long-
term goals of asthma management, including mild dis-
ease, are to achieve good symptom control and minimise
the future risk of exacerbations, fixed airflow limitation
and side effects [2]. However, asthma remains uncon-
trolled in many patients, despite the availability of effect-
ive treatment regimens [1, 3].
Although inhaled corticosteroids (ICS) are an effective
treatment for asthma, poor adherence to prescribed main-
tenance therapy results in under-treatment of the under-
lying inflammation and an increased risk of exacerbations,
disease progression and death [4–9]. In addition, over-
reliance on short-acting β2-agonist (SABA) reliever medica-
tion for symptomatic improvement often leads to a delay in
the introduction of ICS in patients with mild asthma [10].
Consequently, an alternative approach could be to use an
ICS in combination with either a SABA or a rapid- and
long-acting β2-agonist (LABA) as reliever medication with-
out concurrent maintenance treatment, ensuring that ICS
is delivered whenever the patient experiences asthma symp-
toms, and allowing titration of both ICS, and SABA or
LABA, according to patient need.
There is evidence to suggest that a combination of ICS
and a rapid-acting β2-agonist is effective when given ‘as
needed’ in response to asthma symptoms, across all dis-
ease severities. In patients with mild asthma, the BEST
study showed that the as-needed use of beclometasone di-
propionate (BDP) and salbutamol in a single inhaler was
noninferior to regular ICS maintenance therapy [11]. For
mild-to-moderate asthma, another study has shown that
the time to treatment failure was similar when patients re-
ceived as-needed BDP and salbutamol in separate inhalers
compared with a maintenance dose of ICS adjusted at 6-
weekly intervals based on physician assessment [12]. Simi-
larly, as-needed budesonide/formoterol was shown to
reduce fractional exhaled nitric oxide (FeNO) and improve
lung function compared with as-needed formoterol in pa-
tients with so-called intermittent asthma and elevated
baseline FeNO [13]. In moderate-to-severe asthma, as-
needed budesonide/formoterol used in addition tomaintenance therapy reduced the rate of severe exacerba-
tions compared with either formoterol or terbutaline re-
liever therapy, as shown in the Symbicort SMART™
programme [14]. Consequently, there is a need for large-
scale randomised clinical trials to further assess this as-
needed approach in patients with mild asthma, as
highlighted in recent reviews [15, 16].
The SYmbicort Given as needed in Mild Asthma
(SYGMA) programme aims to evaluate the efficacy and
safety of as-needed budesonide/formoterol in patients with
mild asthma. Here, we describe the rationale and design of
two ongoing 52-week phase 3 trials (SYGMA1
[NCT02149199, registered on 16 May 2014] and SYGMA2
[NCT02224157, registered on 19 August 2014]) that are
comparing as-needed budesonide/formoterol with either
maintenance budesonide plus as-needed terbutaline, or as-
needed terbutaline alone. Asthma symptom control [2], as
assessed by well-controlled asthma weeks, and annual se-
vere exacerbation rate are being investigated as primary
endpoints. Secondary endpoints include: average change
from baseline in pre-dose forced expiratory volume in 1 s
(FEV1), Asthma Control Questionnaire (ACQ-5) score,
health-related quality of life, asthma symptom control,
medication intake measured via the Turbuhaler® Usage




Patients meeting the inclusion and exclusion criteria as
detailed in Table 1 were eligible for inclusion in the
SYGMA programme. The same inclusion and exclusion
criteria apply to both SYGMA1 and SYGMA2.
In brief, patients were eligible for inclusion if they
were aged 12 years or older at visit 1 (Table 2, Figs. 1
and 2), with a documented clinical diagnosis of asthma
according to Global Initiative for Asthma (GINA) cri-
teria [17] for at least 6 months prior to visit 1 and with
confirmation of diagnosis by bronchodilator reversibility.
Lung function and reversibility tests performed as part
of visits 2 and 3 can be used as confirmation of asthma
diagnosis if there is no measure of lung function avail-
able before visit 1. Patients must have evidence of need
Table 1 Key inclusion and exclusion criteria for participation in the SYGMA programme
Key inclusion criteria Key exclusion criteria
• Male and female outpatients aged ≥12 years
• A documented clinical history of asthma for at least 6 months prior to
visit 1, diagnosed according to GINA criteria
• Patients in need of GINA (2012) step 2 treatment for the last 30 days
before visit 2, i.e. patients with asthma that is either:
• Well-controlled on mono-maintenance therapy with either a low, stable
dose of an ICS or a LTRA in addition to as-needed use of inhaled short-
acting bronchodilator(s) (SABA and/or short-acting anticholinergic agent)
• Uncontrolled on inhaled short-acting bronchodilator(s) as needed
(SABA and/or short-acting anticholinergic agent)
• Lung function tests at visit 2 (according to the ERS guidelines [38]);
patients pre-treated with:
• Low-dose ICS or LTRA in addition to inhaled short-acting bronchodila-
tor(s) should have pre-bronchodilator FEV1≥ 80%
• An inhaled short-acting bronchodilator only should have pre-
bronchodilator FEV1 ≥ 60% predicted and post-bronchodilator
FEV1≥ 80% predicted
• Reversible airway obstruction at visit 2, defined as an increase in FEV1≥
12% and 200 mL relative to baseline, after inhalation of 1 mg terbutaline
Turbuhaler®. The test can be repeated at visit 3 in case patients fail at
visit 2. If patients fail at both occasions, they can still be included if they
have documented historical reversibility within the last 12 months prior
to visit 3, with an increase in FEV1≥ 12% and 200 mL relative to baseline
after administration of a rapid-acting β2-agonist
• For randomisation at visit 3, patients should fulfil the following criteria:
• Use of as-needed terbutaline Turbuhaler® due to asthma symptoms
on at least 3 separate days during the last week of the run-in period
• Ability to use Turbuhaler® correctly and to complete the eDiary
correctly. Morning and evening data must be recorded for at least
8 days (any 8) of the last 10 days of the run-in period
• Any asthma worsening requiring change in asthma treatment
other than SABA and/or short-acting anticholinergic agent
within 30 days prior to visit 1 or during run-in
• Use of oral, rectal or parenteral GCS within 30 days and/or
depot parenteral GCS within 12 weeks prior to visit 1
• Smoker (current or previous) with a smoking history of ≥10
pack years
• Use of any β-blocking agent, including eye drops
• Any significant disease or disorder (e.g. cardiovascular,
gastrointestinal, hepatic, renal)
• Pregnancy, breast-feeding or planned pregnancy
• For randomisation at visit 3, patients should not fulfil any of the
following criteria:
• Use of ≥6 terbutaline Turbuhaler® as-needed inhalations per
day, for a certain number of days depending on the actual
length of run-in: for ≥2 days out of 14 days; for ≥3 days out
of 15–21 days; for ≥4 days out of 22 or more days of run-in
eDiary electronic diary, ERS European Respiratory Society, FEV1 forced expiratory volume in 1 s, GCS glucocorticosteroid, GINA Global Initiative for Asthma, ICS
inhaled corticosteroid, LTRA leukotriene receptor antagonist, SABA short-acting β2-agonist
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days before visit 2, either by asthma being well-
controlled on mono-maintenance therapy with a low
stable dose of an ICS or a leukotriene receptor antagon-
ist (LTRA) in addition to as-needed short-acting bron-
chodilator (SABA and/or short-acting anticholinergic
agent) (subgroup 1); or by asthma being uncontrolled on
as-needed, inhaled short-acting bronchodilator(s) (sub-
group 2). Additional inclusion criteria included baseline
pre-bronchodilator FEV1 ≥ 80% predicted (for subgroup
1) or ≥60% predicted (for subgroup 2) (Table 1). Exclu-
sion criteria included a recent asthma exacerbation, his-
tory of life-threatening asthma requiring intubation, and
current or past smokers with a smoking history of at
least 10 pack-years.
In both studies, patients who fulfilled all the inclusion
and none of the exclusion criteria at visit 2 entered a 2–4-
week run-in period in order to demonstrate the appropri-
ateness of candidates prior to randomisation (Figs. 1 and
2). Patients were to stop any prescribed asthma medica-
tion (including SABA and maintenance treatment with
ICS or LTRA) that was being used at the time of study
entry, and all patients were to receive as-needed Bricanyl®
Turbuhaler® 0.5 mg during run-in (which corresponds to
the blinded terbutaline Turbuhaler® 0.4 mg, with regards
to the dose delivered). At visit 3, patients will berandomised if they required as-needed terbutaline for the
relief of asthma symptoms on at least three separate days
during the last week of the run-in period; however, pa-
tients will be excluded if, during run-in, they used as-
needed terbutaline six or more times per day on: at least 2
days out of 14 days; at least 3 days out of 15–21 days; at
least 4 days out of 22 or more days (depending on the dur-
ation of run-in). All study medication, including terbuta-
line during run-in, will be delivered via Turbuhaler® and
recorded electronically using the TUM [18].
The study is being performed in accordance with the
Declaration of Helsinki and Good Clinical Practice. The
protocols for the SYGMA 1 and SYGMA 2 trials have
been approved by the oversight authorities in the coun-
tries detailed in Additional file 1: Table S1. All patients
were required to provide written informed consent be-
fore participating in the programme, and recruitment
was not to begin in an individual site before all local ap-
provals had been obtained.
SYGMA1 study design
Target recruitment for SYGMA1 is 3750 patients from
approximately 18 countries. These patients will be ran-
domised to either placebo twice daily (bid) plus as-
needed budesonide/formoterol 160/4.5 μg, placebo bid
plus as-needed terbutaline 0.4 mg, or budesonide 200 μg
Table 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figures for SYGMA1 (A) and SYGMA2 (B)
Enrolment Run-in Randomisation Treatment Follow-up
A
Week −2 to −4 0 4 16 28 40 52 54
Visit 1 2 3 4 5 6 7 8 Phone
Informed consent X
Allocation of enrolment code (IVRS/IWRS) X
Demography (date of birth, gender, race) X
Inclusion/exclusion criteria X X X
Medical, surgical history X




Patient training in eDiary, Turbuhaler®
(inhalation technique), TUM and PEF meter use
X
ACQ-5 and AQLQ(S) at study site X X Only ACQ-5 X X X X
SAEs (from visit 1)/AEs (from visit 2) X X X X X X X X X
Weight and height (height only for adolescents at
visit 8)
X X
Physical examination X X
Pulse and blood pressure X X
Pregnancy test X
Adjustment of current asthma medication X
Randomisation X
Bricanyl® for run-in dispense [d]/return [r] d r
Lung function (FEV1, FVC pre and post Bricanyl®
administration)
X X X X X X X
Reversibility test (calculated at visit 2 and if
needed, calculated at visit 3 as well)
X X
Concomitant medication X X X X X X X
Investigational product (dispense [d]/return [r]/
check [c])
d d/r/c d/r/c d/r/c d/r/c r/c
Intake of maintenance treatment morning
dose
X X X X X
Review of PEF, asthma symptoms, night-time
awakenings, maintenance and ‘as needed’ IP in-
take and Turbuhaler® user technique; re-training
of patient if needed
X X X X X X
Review of patient’s compliance with eDiary X X X X X X
Informed consent (qualitative substudy)a Xa Xa Xa Xa
B
Week −2 to −4 0 8 17 25 34 42 52b 54
Visit 1 2 3 Phone Phone Phone
Written informed consent X
Allocation of enrolment code X
Demography X
Inclusion/exclusion criteria X X X
Medical/surgical history X
Asthma history (including exacerbation history) X
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Table 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figures for SYGMA1 (A) and SYGMA2 (B)
(Continued)
Smoking history X
ACQ-5, AQLQ(S) X X X X X
Health Care resource utilisation questionnaire,
EQ-5D-5L
X X X X
SAE/AEsc Xc Xc X X X X X
Weight and height X Xd
Physical examination X X
Vital signs (pulse and blood pressure) X X
Pregnancy test (if applicable) X
Adjustment of current asthma medication X
Patient training in how to use Turbuhaler®
(inhalation technique) and TUM
X
Bricanyl® for run- in (dispense [d]/return [r]) d r
Randomisation X
Lung function (FEV1, FVC pre and post Bricanyl®
administration)
X X X X X
Reversibility teste X Xe
Collection of severe asthma exacerbations Xf Xf Xf Xf Xf Xf
Concomitant medications X X X X X
Investigational product (dispense [d]/return [r]/
check [c])
d d/r/c d/r/c r/c
Notes:
ACQ-5, Asthma Control Questionnaire 5 questions; AE, adverse event; AQLQ(S), Standardised Asthma Quality of Life Questionnaire; EQ-5D-5L, EuroQol 5-dimensions 5-
level; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IP, investigational product; IWRS/IVRS, Interactive Web and Voice Response System; PEF, morning
peak expiratory flow; SAE, serious adverse event; TUM, Turbuhaler® Usage Monitor, recording use of each blinded study inhalers
aObtaining informed consent of patients into the qualitative substudy is only applicable to the subset of sites selected to participate. Informed consent into the
substudy is to be obtained before any interview-related activities. Informed consent can occur at any time at visit 4 (week 4) or later; however, the qualitative
patient interview conducted with the patient will occur between week 12 and week 50 for each patient who has elected to participate. The exact time point of
the interview will be determined by the contract research organisation
bAfter discontinuation of an investigational drug (ie before visit 6) patients will be followed up according to the original visit schedule including site visits and
phone contacts. Only severe asthma exacerbations, AEs and concomitant medications will be collected. If it is not possible for the patient to visit the study site,
the visit(s) may be performed via phone
cSerious adverse events will be collected from the time of signing informed consent. Adverse events will be collected from visit 2
dHeight only for adolescents
eReversibility test will be performed at visit 2. The test can be repeated at visit 3 in case the patients fail to meet the inclusion criterion at visit 2
fSevere asthma exacerbations will be collected from visit 3 through the entire study
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short-term (2 − 4 weeks) treatment with open-label in-
haled budesonide 200 μg bid is allowed for patients ex-
periencing moderate or severe asthma exacerbations or
having long-term poor asthma control. After this time,
the patient should be evaluated and ‘stepped down’ to
blinded study treatment if possible. If patients require
additional budesonide treatment on two separate occa-
sions, either for a moderate exacerbation or for long-
term poorly-controlled asthma, the investigator should
consider continuing with additional budesonide for the
rest of the study. Weeks with open-label budesonide use
are not defined as well-controlled asthma weeks. Pa-
tients will be instructed to contact the investigator if
using more than 12 inhalations/day of as-needed bude-
sonide/formoterol or terbutaline, or if they feel that they
are in need of medical assistance. An electronic diary(eDiary) will also alert patients to contact their study
physician if symptoms are increasing, and/or if their
lung function deteriorates as measured by morning peak
expiratory flow (PEF). In addition, all patients will be
closely monitored during the course of the study with
treatment visits taking place at 4, 16, 28, 40, and 52
weeks after randomisation (Table 2a).SYGMA2 study design
Target recruitment for SYGMA2 is 4114 patients from
approximately 25 countries. These patients will be ran-
domised to either placebo bid plus as-needed budeso-
nide/formoterol 160/4.5 μg or budesonide 200 μg bid
plus as-needed terbutaline 0.4 mg (Fig. 2). Patients will
be instructed to contact the investigator if using more
than 12 inhalations/day of as-needed budesonide/
Fig. 1 SYGMA1 study design. bid twice daily, E enrolment, EM electronic monitoring twice daily (eDiary), FU follow-up phone call, TUM Turbuhaler®
Usage Monitor, recording use of each blinded study inhalers. †Corresponds to the terbutaline Turbuhaler® 0.4 mg, with regards to the dose delivered
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need of medical assistance.
Treatment visits will take place at 17, 34, and 52 weeks
after randomisation. Between site visits, study staff will
contact patients by phone to record additional asthma
treatment and hospitalisation/emergency treatment due
to asthma (including severe asthma exacerbation data;
Table 2b).
Efficacy assessments
Details of the primary and secondary efficacy endpoints
included in the SYGMA1 and SYGMA2 studies are pre-
sented in Table 3. In SYGMA1, the primary objective is to
demonstrate that as-needed budesonide/formoterol is
superior to as-needed terbutaline in terms of asthma con-
trol as measured by well-controlled asthma weeks [19],
achieved when two or more of the following criteria are
fulfilled: no more than 2 days with a daily asthmaFig. 2 SYGMA2 study design. bid twice daily, E enrolment, FU follow-up ph
blinded study inhalers. †Corresponds to the terbutaline Turbuhaler® 0.4 mgsymptom score >1; no more than 2 days of as-needed
medication use, up to a maximum of four occasions per
week (multiple occasions per day are regarded as separate
occasions); morning PEF ≥80% predicted every day. Both
of the following criteria must also be fulfilled: no night-
time awakenings due to asthma; no additional inhaled
and/or systemic corticosteroid treatment due to asthma
[19]. A secondary objective is to establish the noninferior-
ity of as-needed budesonide/formoterol versus mainten-
ance budesonide plus as-needed terbutaline using the
same outcome measure. The primary objective of
SYGMA2 is to demonstrate that as-needed budesonide/
formoterol is noninferior to twice-daily budesonide plus
as-needed terbutaline at reducing the annual severe
asthma exacerbation rate (Table 3). Secondary efficacy
and safety outcome measures are shown in Table 3.
In both SYGMA1 and SYGMA2, a severe asthma ex-
acerbation is defined using American Thoracic Society/one call, TUM Turbuhaler® Usage Monitor, recording use of each
, with regards to the dose delivered
Table 3 Endpoints of the SYGMA programme
SYGMA1 SYGMA2





• Evaluation of asthma













budesonide bid plus as-needed
terbutaline
• Evaluation of asthma







• Time to first severe asthma
exacerbation
• Average change from
baseline in pre-dose FEV1
• Time to study specific
asthma-related
discontinuation
• Average change from
baseline in number of
inhalations of as-needed
medication
• Change from baseline in
percent of as-needed free
days
• Percentage of controller use
days
• Average change from
baseline in ACQ-5 score and
responders based on MID
• Average change from
baseline in AQLQ score
• Total ICS load and number
of days with systemic
corticosteroid treatment
As-needed budesonide/formoterol vs
as-needed terbutaline or budesonide
bid plus as-needed terbutaline
• Time to first severe asthma
exacerbation
• Time to first moderate or
severe asthma exacerbation
• Average change from
baseline in pre-dose FEV1
• Average change from
baseline in morning and
evening PEF
• Average change from
baseline in number of
inhalations of as-needed
medication
• Average change from
baseline in symptom score
• Percentage of night-time
awakenings due to asthma
• Percentage of symptom-
free days
• Percentage of as-needed
free days
• Percentage of asthma
control days
• Percentage of controller use
days




• Time to additional steroids
for asthma
• Average change from
baseline in ACQ-5 score and
responders based on MID
• Average change from
baseline in AQLQ score
• Total ICS load and number





as-needed terbutaline or budesonide
bid plus as-needed terbutaline
• Adverse events (nature,
incidence and severity)






• Adverse events (nature,
incidence and severity)















ACQ-5 Asthma Control Questionnaire 5-item version, AQLQ Asthma Quality of Life Questionnaire standard version, bid twice daily, FEV1 forced expiratory volume in
1 s, ICS inhaled corticosteroid, MID minimal important difference, PEF peak expiratory flow
Daily asthma symptom score = the sum of the morning and evening symptom score
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teria [20] as worsening of asthma that is associated with
a medical intervention, requiring either the use ofsystemic corticosteroids for at least 3 days (or an injec-
tion of depot corticosteroids), or inpatient hospitalisa-
tion or an emergency department (ED) visit (or other
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required systemic corticosteroids. Moderate exacerba-
tions will also be assessed in SYGMA1, and are defined
as a deterioration of asthma requiring a change in treat-
ment, i.e. initiation of open-label ICS, to avoid progres-
sion to a severe exacerbation. Spirometry assessments in
both studies will be performed according to ATS/ERS
guidelines [21] on the day of study visits (SYGMA1:
visits 2–8; SYGMA2: visits 2–6).
In SYGMA1 only, patients will complete an eDiary twice
daily for PEF, asthma symptoms and night-time awakenings
due to asthma symptoms. A symptom-free day is defined
as a day and night with no asthma symptoms, and a night
with no awakenings due to asthma symptoms. Similarly, an
asthma-control day is defined as the fulfilment of all of the
following criteria: a day and night with no asthma symp-
toms; a night with no awakenings due to asthma symp-
toms; a day and night with no as-needed medication use.
Poorly-controlled asthma weeks, a secondary variable in
SYGMA1 only, are defined as the documentation of one of
the following conditions: at least two consecutive days with
night-time awakening due to asthma symptoms; as-needed
medication use for symptom relief on at least three occa-
sions per day for at least two consecutive days; additional
systemic corticosteroids required for a severe asthma ex-
acerbation. In SYGMA1, ACQ-5 and Standardised Asthma
Quality of Life Questionnaires (AQLQ) will be self-
administered within the eDiary at scheduled visits. In
SYGMA2, ACQ-5 and AQLQ questionnaires will be self-
administered using the electronic Patient Reported Out-
come (ePRO) device at scheduled visits.
Use of as-needed or randomised maintenance treat-
ment, and terbutaline use during run-in, will be recorded
using the TUM (SmartTurbo™, Adherium, New Zealand)
in both studies. The TUM is a validated electronic data
logger designed to be attached to a Turbuhaler® [18, 22].
The TUM contains an electronic clock that logs the date
and time when the Turbuhaler® base grip is rotated back
and forth. Use of open-label budesonide will be recorded
in the electronic Case Report Form (eCRF). Patients will
receive appropriate training for all devices (eDiary, PEF
meter, TUM, ePRO device) at visit 2.Safety assessments
Safety assessments included in both studies are detailed
in Table 3. AEs will be recorded from visit 2, throughout
the treatment and follow-up periods, until the last phone
follow-up, or last contact. Serious AEs (SAEs) will be re-
corded from the time of informed consent. All AEs will
be recorded in the eCRF. Physical examination, blood
pressure, and pulse rate measurements will be per-
formed before run-in (visit 2) and at the end of treat-
ment (SYGMA1: visit 8; SYGMA2: visit 6). Follow-upphone contact for AEs will be performed 2 weeks after
completion of study treatment. An independent Adjudi-
cation Committee will review any fatal events occurring
during the SYGMA studies to determine whether these
events were asthma-related.
Exploratory assessments
In SYGMA1, a qualitative substudy is being conducted in a
small subset of patients. The exploratory objective of this
substudy is to further evaluate when and why patients use
the study medications, using a qualitative interview
approach [23]. In SYGMA2, information on health care re-
source utilisation as well as health status (EuroQol 5-
dimensions 5-level health survey: EQ-5D-5L) will be
collected at randomisation and at each treatment visit to
enable the cost-effectiveness of the interventions to be
assessed. Patients will be asked about ambulatory-setting or
home consultations with specialists, primary care physi-
cians or other health care professionals, and phone consul-
tations with physicians or nurses as well as health care
resource use in terms of: ambulance services; ED visits;
hospital admissions including intensive care. Patients in
paid employment and education will be asked how much
time they have missed due to their asthma. The EQ-5D-5 L
will assess mobility, self-care, usual activity, pain/discom-
fort, and anxiety/depression, and will be self-administered
using the paper version.
Discontinuations
Study-specific criteria for discontinuations in SYGMA1
are: a severe asthma exacerbation with a duration of more
than 3 weeks; two severe asthma exacerbations within a
period of 3 months; or three severe asthma exacerbations
in total during the study. Study-specific criteria for discon-
tinuations in SYGMA2 are: a severe asthma exacerbation
with duration of more than 3 weeks; three severe asthma
exacerbations within a period of 6 months.
Sample size estimates
In SYGMA1, 3750 patients (625 patients/treatment
group/pre-study treatment group) are required to give
greater than 95% power to detect superiority of as-needed
budesonide/formoterol compared with as-needed terbuta-
line and 90% power to establish noninferiority of as-
needed budesonide/formoterol compared with budesonide
plus as-needed terbutaline for well-controlled asthma
weeks, with a pre-defined noninferiority limit of 0.8, i.e.
the lower 95% confidence interval (CI) of the odds ratio
for budesonide/formoterol versus budesonide plus terbu-
taline is ≥0.8. Assuming that equal numbers of patients
are recruited to each of the subgroups (stratified by pre-
study treatment), this sample size also gives 80% power to
detect a difference between as-needed budesonide/formo-
terol and as-needed terbutaline, and 80% power to
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terol compared with budesonide plus as-needed terbuta-
line, with a pre-defined noninferiority limit of 0.78.
SYGMA2 was initially powered to demonstrate super-
iority of as-needed budesonide/formoterol compared
with budesonide plus as-needed terbutaline as measured
by the annualised severe exacerbation rate; 4114 patients
(2057 patients/treatment group) were estimated to be re-
quired to achieve 90% power to detect a difference in
annualised severe asthma exacerbation rate between
treatments, assuming an exacerbation rate of 0.16 per
year among patients treated with budesonide, with a
25% reduction in risk for patients receiving as-needed
budesonide/formoterol. To account for uncertainty over
the assumed exacerbation rates as well as the dispersion
parameter, the overall exacerbation rate was planned to
be monitored during the study in a blinded fashion,
allowing for an increase of the sample size by a max-
imum of 50%. A blinded sample size review of SYGMA
2, performed according to the study protocol and prior
to enrolling the last patient, indicated that there would
be adequate power to test a noninferiority hypothesis
based on the design and assumptions specified in the
protocol. The SYGMA 2 protocol was amended to in-
clude a noninferiority test as the primary analysis, using
a pre-defined noninferiority limit of 1.2.
Statistical analyses
The primary outcome measure in SYGMA1, well-
controlled asthma weeks (as-needed budesonide/formo-
terol versus as-needed terbutaline (superiority) and as-
needed budesonide/formoterol versus maintenance bude-
sonide plus as-needed terbutaline (noninferiority)), will be
analysed by a repeated measures logistic regression model
with: treatment, pre-study treatment, and region as fixed
effects; study week as a categorical time variable; and pa-
tient as a random effect. The statistical inference will be
based on the estimated odds ratio and corresponding 95%
CI averaged over the whole randomised treatment period.
In SYGMA2, the primary outcome measure of severe
exacerbation rate (as-needed budesonide/formoterol ver-
sus maintenance budesonide plus as-needed terbutaline
(noninferiority)) will be analysed by a negative binomial
regression model with treatment, pre-study treatment
group, and region as factors. Annual severe exacerbation
rates will be estimated and treatment effect will be
expressed as the rate ratio and corresponding one-sided
noninferiority interval and two-sided 95% CI. If noninfe-
riority is achieved, then a test for superiority of as
needed budesonide/formoterol versus maintenance
budesonide will be performed.
The following secondary efficacy endpoints will be
assessed in SYGMA1 only. The moderate-to-severe and
severe asthma exacerbation rate will be analysed by anegative binomial regression model with treatment, pre-
study treatment, and region as factors, and presented as
rate ratios and 95% CIs. Time to first moderate-to-
severe exacerbation and time to administration of add-
itional steroids will be analysed by a Cox proportional
hazards model with treatment, pre-study treatment
group, and region as factors; hazard ratios (HRs) and
95% CIs will be estimated. Change in eDiary variables
from run-in to the mean value of available data during
treatment will be analysed by analysis of covariance
(ANCOVA) with treatment, pre-study treatment, and re-
gion as factors, and mean values during run-in as a con-
tinuous covariate. Least squared means (LSMs) by
treatment and differences in LSMs between treatments
will be estimated, along with corresponding 95% CIs.
Poorly-controlled asthma weeks will be analysed in the
same manner as the primary outcome measure, well-
controlled asthma weeks.
The remaining secondary efficacy endpoints will be
analysed in both SYGMA1 and SYGMA2. Time to first
severe asthma exacerbation and time to discontinuation
due to asthma-related events will be analysed by a Cox
proportional hazards model with treatment, pre-study
treatment group, and region as factors; HRs and 95%
CIs will be estimated. The treatment effect and 95% CI
for average change from baseline in pre-dose FEV1,
ACQ-5, and AQLQ will be analysed using a mixed-
model repeated measures analysis, with the analysis in-
cluding terms for treatment, pre-study treatment group,
region, visit, and treatment by visit. FEV1 data will be
analysed with baseline FEV1 included as a covariate. For
ACQ-5 and AQLQ, change from baseline to the end of
treatment will also be analysed by ANCOVA with treat-
ment, pre-study treatment group, and region as factors
and baseline as a continuous variable. Responder vari-
ables, based on minimal important difference for ACQ-5
and AQLQ, will be analysed using a logistic regression
model with treatment, region, and pre-study treatment
as factors, and baseline as a covariate. From the logistic
regression model, treatment effects will be estimated by
odds ratio and its corresponding 95% CI. The percentage
of controller-use days and as-needed use will be analysed
by ANCOVA with treatment, pre-study treatment group,
and region as factors; LSMs by treatment and differences
in LSMs between treatments will be estimated along
with corresponding 95% CIs. In SYGMA1, sensitivity
analyses will be performed to explore the impact of the
individual components of well-controlled asthma weeks,
paying specific attention to the as-needed component. In
SYGMA2, a sensitivity analysis for the primary variable
will include all data for patients who discontinue study
medication but remain in the study.
For both studies, AEs will be listed for each patient
and summarised by means of count summaries by
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event. Other safety variables will be summarised as ap-
propriate. The exploratory endpoints (resource utilisa-
tion and health-related quality of life) will be reported
descriptively as part of SYGMA2.
In order to assess the consistency of the treatment ef-
fect in the two subgroups (defined by pre-study treat-
ment), a pre-study treatment × treatment interaction
term will be included in the models for the primary vari-
ables in SYGMA1 and SYGMA2. Several other subgroup
analyses are also planned, including age, gender, severe
exacerbation history in the 12 months prior to screen-
ing, baseline symptom history (ACQ), time since asthma
diagnosis, smoking history, region, pre-bronchodilator
FEV1, and SABA use during run-in.
Discussion
Both clinicians and patients may underestimate the risks
and burden associated with mild asthma. Indeed, despite
the proven efficacy of ICS maintenance therapy in
asthma, there remains an unmet medical need due to
over-reliance on SABA reliever medication and poor ad-
herence to prescribed ICS [24]. Initial reports suggest
that the as-needed use of combination ICS/β2-agonist
with rapid onset of action may have advantages over
regular ICS therapy for the treatment of mild asthma
[11, 12]. For example, in a 6-month trial of 455 patients
with mild asthma, the symptom-driven use of BDP/sal-
butamol was as effective for asthma exacerbations and
morning PEF as maintenance BDP or BDP/salbutamol
plus as-needed salbutamol [11], and significantly better
than as-needed salbutamol.
Large randomised controlled trials investigating the as-
needed use of different ICS/LABA combinations, taken in
response to symptoms, as an alternative to current step 2
treatment in patients with mild asthma are currently
lacking and are an important research priority [15, 16].
SYGMA1 and SYGMA2 are the first major randomised
controlled trials to assess the as-needed use of budesonide/
formoterol in patients with mild asthma. For SYGMA2, se-
vere exacerbations are the primary outcome measure. How-
ever, for SYGMA1, well-controlled asthma weeks was
chosen as the primary outcome measure due to its rele-
vance to all patients. Consequently, the primary outcomes
of the SYGMA studies address both aspects of the goals of
asthma management, as defined by GINA and other treat-
ment guidelines, which are to achieve good symptom con-
trol and to minimise the future risk of exacerbations.
Well-controlled asthma weeks has previously been used
in several studies as a composite measure of asthma control
[19, 25, 26], but, to the best of our knowledge, this outcome
measure has never been used in studies that include
electronic monitoring of reliever use. Well-controlled
asthma weeks takes into account symptoms, night-timeawakenings, lung function, and as-needed reliever medica-
tion use, and corresponds to the ‘symptom control’ compo-
nent in current guidelines, and excludes weeks with
additional corticosteroid use or with night-time awaken-
ings. However, the definition of well-controlled asthma
weeks is based on current guidelines, where ‘as needed’
medication is usually a short-acting bronchodilator that
does not contain an anti-inflammatory component, and so
it may not be applicable to patients receiving as-needed
budesonide/formoterol. Consequently, a sensitivity analysis
will be performed that excludes the as-needed use of study
medication from the definition of well-controlled asthma
weeks. In addition, although patients are known to over-
report their preventer use, they often under-report their
reliever use [27]; as a result, there may be fewer well-
controlled asthma weeks with reliever use recorded
electronically than if this element had been based on self-
report. It should also be noted that the TUM is electronic-
ally recording the turning of the Turbuhaler® grip, and not
the actual process of inhalation, which may lead to over
reporting of medication use.
A strength of the SYGMA studies is their long duration
(52 weeks), which will allow reliable assessment of exacer-
bations. Reducing future risk by the prevention of asthma
exacerbations is a key goal of asthma management [2] as
exacerbations constitute the greatest risk to patients, are a
cause of anxiety to patients and their families, and result
in the greatest cost to the health care system [20]. There is
some uncertainty over the frequency of severe exacerba-
tions in mild asthma, with estimates ranging from 0.12 to
0.77 episodes per patient-year [1, 3, 28]. It has been sug-
gested that severe exacerbations in mild asthma represent
30–40% of all asthma exacerbations that require an emer-
gency consultation [1]. Twelve months is regarded as the
minimum period for evaluation of annualised exacerba-
tion rates [29]; this is particularly important in mild
asthma, in which exacerbations are relatively rare events
[30]. The designs of the SYGMA studies utilise clinic visits
(SYGMA1 and SYGMA2), eDiary alerts (SYGMA1 only),
and additional phone contacts (SYGMA2 only) to ensure
that asthma exacerbation events are correctly collected.
The 52-week duration and use of an electronic moni-
toring device (TUM) on all blinded study inhalers will
also allow evaluation of usage of the randomised main-
tenance and as-needed medications over all seasons of a
year. Patients with mild asthma may be willing to accept
mild symptoms and have poor adherence to mainten-
ance ICS [31]. It is, therefore, hoped that the as-needed
approach will better match patient behaviour and help
to overcome the problems associated with poor adher-
ence. Patients will be aware that inhaler use is being re-
corded, which may temporarily improve adherence with
maintenance treatment; however, this is likely to occur
only for a short period of time [32].
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the design of the studies. For example, a 2–4-week run-in
period has been included in both studies to allow baseline
data to be collected and to ensure that patients are in need
of GINA step 2 treatment. Furthermore, in SYGMA1 only,
patient recruitment will be balanced to allow stratification
based on pre-study treatment, i.e. asthma that is uncon-
trolled on as-needed short-acting bronchodilator or asthma
that is well-controlled on mono-maintenance with either a
low-dose ICS or LTRA plus as-needed short-acting bron-
chodilator. Health economic data will be collected in
SYGMA2, to allow comparison of the cost-effectiveness of
the different regimens under different pricing structures.
Data for the use of as-needed budesonide/formoterol
compared with as-needed SABA in a similar patient popu-
lation and in studies with a similar design to SYGMA are
unavailable; as such, the SYGMA1 study includes a
‘pseudo’ placebo arm that allows the assessment of the su-
periority of as-needed budesonide/formoterol compared
with as-needed terbutaline. However, patients in the
‘pseudo’ placebo arm may experience a deterioration in
asthma control, and so it is important to ensure that there
is a mechanism by which they receive rapid medical atten-
tion whenever necessary. Consequently, triggers in the
eDiary generate alerts that warn patients of worsening
asthma, prompting them to contact the investigator who
may prescribe additional inhaled and/or systemic cortico-
steroid treatment to patients experiencing an exacerbation
or with poor long-term asthma control. In addition, pa-
tients will be instructed to contact the investigator at any
time should they require medical assistance or if they use
more than 12 as-needed inhalations per day. The
SYGMA2 study is designed to support the SYGMA1 regu-
latory study but reduce the burden of study requirements,
e.g. fewer scheduled visits and absence of the eDiary/pa-
tient reminders. However, because of the regulatory re-
quirements for a double-blind, placebo-controlled study,
all participants will be required to take a regular mainten-
ance inhaler containing either placebo or budesonide to
ensure blinding of the treatment groups. Consequently,
additional studies with a pragmatic, open-label design will
be needed to evaluate natural patient behaviour with an
as-needed regimen, so that the results can be generalised
to clinical practice, and two such studies (Universal Trial
Numbers: U1111-1170-2118; U1111-1174-2273) are un-
derway [33].
In SYGMA 2, daily low-dose budesonide (plus as-needed
terbutaline) was selected as the active comparator treat-
ment. The use of regular daily low-dose budesonide is well-
established, having been shown to be highly effective in re-
ducing the risk of asthma-related exacerbations, including
in patients with mild persistent asthma (as demonstrated in
the START study) [3]. Furthermore, additional evidence has
recently emerged confirming the appropriateness of low-dose budesonide maintenance therapy for patients with
mild asthma and less frequent symptoms [34, 35].
Thus, the availability of an as-needed ICS/LABA single
inhaler that could provide comparable control to current
standard-of-care treatment with low-dose daily ICS plus as-
needed medication would represent a breakthrough in the
treatment of mild asthma, providing patients and clinicians
with an alternative more convenient option with the poten-
tial for improved adherence. The blinded sample size re-
view conducted during SYGMA 2 demonstrated adequate
power to test a noninferiority hypothesis based on the de-
sign and assumptions specified in the study protocol. In
view of this, the decision was taken to change the primary
objective for SYGMA 2 to assess whether budesonide/for-
moterol as needed will be noninferior to budesonide given
as regular maintenance with regard to the annual severe ex-
acerbation rate. To maintain the validity of the primary
analysis, the protocol was amended prior to trial comple-
tion and unblinding, and the noninferiority margin relative
to the control arm was pre-specified [36, 37].While a non-
inferiority margin for exacerbation reduction in patients
with mild asthma has not been previously defined, a margin
of 20% was considered to be an appropriate choice because
a difference between treatments smaller than this would be
judged to be of questionable clinical relevance in this popu-
lation. If the noninferiority criteria are met in SYGMA 2,
superiority of as-needed budesonide/formoterol versus
budesonide will also be assessed. The benefit/risk will also
be assessed in the context of other endpoints evaluating
asthma control as well as steroid load, the pattern of ‘as
needed use’ and controller use days.
In conclusion, the SYGMA programme should help to
determine the efficacy and safety of as-needed budeso-
nide/formoterol combination therapy in mild asthma, as
an alternative to regular low-dose ICS treatment. Patient
recruitment is completed and completion of the phase 3
studies is planned in 2017.
Trial status
The first patients were recruited to SYGMA1 and
SYGMA2 in July 2014 and November 2014, respectively.
Recruitment to both trials is completed (June 2016).
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